A Phase 2, Multicohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With Clinical High-Risk Multiple Myeloma (KarMMa-2)
Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (KarMMa-2)
Sponsor: Celgene
Enrolling: Male and Female Patients
IRB Number: AAAR9953
U.S. Govt. ID: NCT03601078
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to determine if the investigational therapy called bb2121 is effective in treating multiple myeloma. bb2121 is a type of therapy known as chimeric antigen receptor (CAR) T cell therapy. T cells are a kind of white blood cell which form part of your body's immune system. Your T cells will be separated from the rest of the immune cells and then modified to make the bb2121 T cells. The bb2121 T cells manufactured for you will be shipped to the study site when you are ready for the treatment and infused back into your blood.
Investigator
Ran Reshef, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Were you diagnosed with multiple myeloma? Yes No
Did your cancer return after your most recent treatment regimen, or has your cancer not responded to your most recent treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162